NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Knight Therapeutics Inc (TO: GUD)

 
GUD Technical Analysis
5
As on 2nd Jul 2025 GUD STOCK Price closed @ 6.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 5.63 & Strong Buy for SHORT-TERM with Stoploss of 5.43 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

GUDSTOCK Price

Open 5.81 Change Price %
High 6.02 1 Day 0.17 2.92
Low 5.81 1 Week 0.15 2.56
Close 6.00 1 Month 0.23 3.99
Volume 50691 1 Year 0.82 15.83
52 Week High 6.27 | 52 Week Low 5.11
 
TO Canada Most Active Stocks
YRI 7.89 0.13%
TD 101.10 0.94%
TRP 65.19 -1.94%
UEX 0.50 16.28%
CVE 19.39 4.64%
SU 52.00 1.94%
WCP 9.22 0.77%
ENB 60.85 -1.46%
SJR-B 40.48 0.02%
BCE 31.04 2.78%
 
TO Canada Top Gainers Stocks
CUB 0.21 950.00%
CUB 0.21 950.00%
AOI 13.38 611.70%
AOI 13.38 611.70%
MOGO 3.47 99.43%
MOGO 3.47 99.43%
GGA 0.03 50.00%
MIN 0.20 42.86%
MIN 0.20 42.86%
MIN 0.20 42.86%
 
TO Canada Top Losers Stocks
MOZ 0.16 -80.25%
MOZ 0.16 -80.25%
BNG 0.01 -50.00%
LEV 0.34 -29.17%
LEV 0.34 -29.17%
LEV 0.34 -29.17%
TXP 0.24 -20.00%
TXP 0.24 -20.00%
TMD 0.04 -20.00%
TMD 0.04 -20.00%
 
 
GUD
Daily Charts
GUD
Intraday Charts
Whats New @
Bazaartrend
GUD
Free Analysis
 
GUD Important Levels Intraday
RESISTANCE6.40
RESISTANCE6.27
RESISTANCE6.19
RESISTANCE6.11
SUPPORT5.89
SUPPORT5.81
SUPPORT5.73
SUPPORT5.60
 
GUD Forecast July 2025
4th UP Forecast7.31
3rd UP Forecast6.89
2nd UP Forecast6.63
1st UP Forecast6.37
1st DOWN Forecast5.63
2nd DOWN Forecast5.37
3rd DOWN Forecast5.11
4th DOWN Forecast4.69
 
GUD Weekly Forecast
4th UP Forecast6.39
3rd UP Forecast6.26
2nd UP Forecast6.19
1st UP Forecast6.11
1st DOWN Forecast5.89
2nd DOWN Forecast5.81
3rd DOWN Forecast5.74
4th DOWN Forecast5.61
 
GUD Forecast2025
4th UP Forecast8.66
3rd UP Forecast7.81
2nd UP Forecast7.28
1st UP Forecast6.75
1st DOWN Forecast5.25
2nd DOWN Forecast4.72
3rd DOWN Forecast4.19
4th DOWN Forecast3.34
 
 
GUD Other Details
Segment EQ
Market Capital 639514880.00
Sector Healthcare
Industry Drug Manufacturers-Specialty & Generic
Offical website >
 
GUD Address
GUD
 
GUD Latest News
 
Your Comments and Response on Knight Therapeutics Inc
 
GUD Business Profile
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Bijuva for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uterus; IMVEXXY to treat postmenopausal moderate to severe dyspareunia; IBSRELA for the treatment of irritable bowel syndrome with constipation in adults; TRELSTAR to treat advanced prostate cancer and for pain associated with endometriosis; ILUVIEN for the treatment of vision loss due to diabetic macular oedema; and NERLYNX to treat early-stage breast cancer. The company also provides Burinex, for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome; PROBUPHINE, to treat opioid addiction; and MOVANTIK for the treatment of opioid-induced constipation. In addition, it offers Vidaza to treat myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven to treat advanced or metastatic breast cancer; Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma; Ladevina to treat multiple myeloma; Zyvalix for metastatic prostate cancer; Karfib to treat relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; AmBisome and Cresemba to treat fungal infection; and Impavido for leishmaniasis. Further, the company provides Ursofalk to treat biliary cirrhosis; Salofalk for ulcerative colitis; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada. Address: 3400 De Maisonneuve Boulevard West, Montreal, QC, Canada, H3Z 3B8
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service